Stoke Therapeutics shareholders back 2026 proposals

Stoke Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 3, 2026.

Rhea-AI Filing Summary

Stoke Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 3, 2026. Stockholders elected directors G. Clare Kahn, Ph.D., Adrian Krainer, Ph.D., and Julie Anne Smith, each receiving tens of millions of shares voted in favor versus relatively small withheld votes, plus broker non-votes.

Stockholders also approved one proposal with 55,121,163 shares for, 2,036 against, and 51,714 abstaining, and another with 36,436,275 shares for, 13,565,293 against, 29,415 abstaining, and 5,143,930 broker non-votes. The filing confirms that these meeting outcomes are now formally recorded.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Votes for G. Clare Kahn, Ph.D.: 49,722,339 shares Votes for Adrian Krainer, Ph.D.: 36,531,612 shares Votes for Julie Anne Smith: 43,500,649 shares +3 more

6 metrics

Votes for G. Clare Kahn, Ph.D. 49,722,339 shares Director election at 2026 Annual Meeting

Votes for Adrian Krainer, Ph.D. 36,531,612 shares Director election at 2026 Annual Meeting

Votes for Julie Anne Smith 43,500,649 shares Director election at 2026 Annual Meeting

Proposal vote with strongest support 55,121,163 shares for Key proposal at 2026 Annual Meeting

Opposing votes on another proposal 13,565,293 shares against Second proposal at 2026 Annual Meeting

Broker non-votes reported 5,143,930 shares Director and proposal voting tallies

Key Terms

Annual Meeting of Stockholders, Broker Non-Votes, Emerging growth company, Common Stock, $0.0001 par value per share

4 terms

Annual Meeting of Stockholders regulatory

"On June 3, 2026, Stoke Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders"

Broker Non-Votes regulatory

"Nominees ... Shares For ... Shares Withheld ... Broker Non-Votes"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

Emerging growth company regulatory

"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ... Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Common Stock, $0.0001 par value per share financial

"Title of each class ... Common Stock, $0.0001 par value per share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Stoke Therapeutics (STOK) announce from its 2026 Annual Meeting?

Stoke Therapeutics reported voting results from its 2026 Annual Meeting. Shareholders elected three directors and approved two additional proposals, with each item receiving strong support measured in tens of millions of shares voted in favor and relatively small numbers voted against or withheld.

Were Stoke Therapeutics (STOK) director nominees elected at the 2026 meeting?

Yes, all three named director nominees were elected. G. Clare Kahn, Ph.D., Adrian Krainer, Ph.D., and Julie Anne Smith each received substantial “For” votes relative to “Withheld” votes, alongside broker non-votes reported in the filing’s detailed tabulation.

How many shares supported a key proposal at Stoke Therapeutics (STOK) in 2026?

One proposal received 55,121,163 shares voted in favor. Only 2,036 shares were voted against and 51,714 abstained, indicating very strong shareholder support based on the voting breakdown disclosed for the 2026 Annual Meeting.

What were the vote results for another major proposal at Stoke Therapeutics (STOK)?

Another proposal received 36,436,275 votes for and 13,565,293 against. There were 29,415 abstentions and 5,143,930 broker non-votes, showing a clear approval margin while still reflecting a meaningful block of shares voting against.

Where is Stoke Therapeutics (STOK) listed and what shares are registered?

Stoke Therapeutics’ common stock is listed on the Nasdaq Global Select Market. The filing notes its common stock, par value $0.0001 per share, trades under the ticker STOK pursuant to Section 12(b) registration under the Securities Exchange Act.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 04:08 PM EDT Learn about SEC filing dates

false 0001623526 0001623526 2026-06-03 2026-06-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 3, 2026

Stoke Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-38938		47-1144582
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

45 Wiggins Ave Bedford, Massachusetts		01730
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (781) 430-8200

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		STOK		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 3, 2026, Stoke Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders, and the following proposals were adopted:

1. Election of three Class I directors, G. Clare Kahn, Ph.D., Adrian Krainer, Ph.D. and Julie Anne Smith, each to serve a three-year term, which will expire upon the earlier of the 2029 annual meeting of stockholders or until such time as their respective successors have been duly elected and qualified or their earlier resignation or removal:

Nominees		Shares For		Shares Withheld		Broker Non-Votes
G. Clare Kahn, Ph.D.		49,722,339		308,644		5,143,930
Adrian Krainer, Ph.D.		36,531,612		13,499,371		5,143,930
Julie Anne Smith		43,500,649		6,530,334		5,143,930

2. Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026:

Shares For		Shares Against		Shares Withheld/Abstaining
55,121,163		2,036		51,714

3. Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 22, 2026:

Shares For		Shares Against		Shares Withheld/Abstaining		Broker Non-Votes
36,436,275		13,565,293		29,415		5,143,930

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 4, 2026

STOKE THERAPEUTICS, INC.
By:		/s/ Thomas E. Leggett
		Thomas E. Leggett
		Chief Financial Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 16.8 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 10.6 KB